Physician profile
Julio A Ramirez
NPI 1962494948
$2,489.27
in general payments reported to CMS, 2019-2025
17 companies · $744 in 2025
The $744 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $12.92 · 2021: $417 · 2022: $173 · 2023: $68.11 · 2024: $257 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,068.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $856.86 | 2019-2021 | |
| Novo Nordisk INC | $286.18 | 2021-2025 | Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $272.91 | 2025 | Recorlev |
| Exact Sciences Corporation | $194.61 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $189.77 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $149.10 | 2025 | Voquezna |
| Intra-Sana Laboratories | $134.18 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Gilead Sciences, INC. | $85.79 | 2019 | |
| Abbvie INC. | $63.28 | 2021 | |
| Lilly USA, LLC | $46.04 | 2024-2025 | Zepbound, Mounjaro |
| Amgen INC. | $41.33 | 2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $40.59 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.98 | 2021 | |
| Janssen Pharmaceuticals, INC | $34.88 | 2021 | |
| Pfizer INC. | $28.80 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $15.05 | 2021 | |
| Amarin Pharma, INC. | $12.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.